Some sources estimate that TBI is ten times as prevalent as spinal cord injury
and on an annual basis, at least 150 people per 100,000 population are treated
in hospitals for TBI. In the United States, statistics provided by the
National Centers for Disease Control (CDC) report that - on an annual basis -
some one million people are impacted by TBI.
As a consequence of increased military engagement, more soldiers are returning
from combat theaters with TBIs. It has been estimated that up to 83 percent of
soldiers returning from Afghanistan and Iraq exhibit a variety of brain injury
symptoms. To add to this picture, increased attention is being paid to
athletes affected by TBI and the link to early-onset dementia.
Currently, no effective TBI therapy exists, with patients treated through a
combination of surgery, rehabilitation and pharmacological agents managing
post-trauma conditions such as depression. Consequently, the considerable
target population leads Arrowhead Publishers to estimate that the global
market value for TBI therapy is in the region of US$1-2 billion, with the
majority of this accounted for by potential demand across Europe and in the
United States.
Traumatic Brain Injury: R&D Pipeline Assessment and Market Prospects takes a
closer look at TBI and its future treatment prospects. It provides a thorough
examination of its causes, symptoms, prognosis, treatment, epidemiology and
unmet clinical need. In addition, it provides the reader with an overview of
key potential markets for TBI therapeutics and assesses various therapies
currently in development for TBI. Future trends in TBI research are also
discusses at length. Finally, financial forecasts for the TBI therapeutic
market are provided along with an analysis of the challenges and opportunities
facing developers of TBI therapies.
What questions does this report answer?
What are the major issues involved in the research and development of more
effective TBI therapeutics?
What is the current status of the TBI pipeline?
What types of TBI therapeutics are currently in research and development?
What is the anticipated market for potential TBI treatments?
Which TBI pipeline candidates are having the best clinical trial results?
Highlights of this report include:
A discussion of the problems associated with the current treatment options
for TBI
Focused analysis of the global prevalence of TBI
Identification of the potential key markets for TBI product candidates
Valuable input from leaders in TBI research
Discussion of the wider social and economic considerations leading to
increased interest in TBI
Reasons to buy this report:
It provides a comprehensive assessment of the challenges and opportunities
for those engaged in the field of TBI R&D
Discusses key candidates and their commercialization prospects
Describes emerging trends in R&D
Unique features of this report include:
Critical assessment of likely success of leading clinical candidates
Forecasts of the global and US markets for TBI therapies
Thorough discussion of important areas of research and development in TBI
8.4.2 HUPERZINE A/CHILDREN' S HOSPITAL BOSTON (CHB)
8.4.3 PEPTIDOMIMETICS/ARDANE
8.4.4 REMYELATION/ACORDA
8.4.5 MULTISTEM/ATHERSYS
8.5 OTHER AREAS OF RESEARCH
8.5.1 STEM CELL TREATMENT
8.5.2 HYPERBARIC OXYGEN (HBO) CHAMBER
8.5.3 RIBAVIRIN
8.6 FAILED RESEARCH
8.6.1 SALINE SOLUTIONS
8.6.2 SLV334
9. THE TBI MARKET: FINANCIAL FORECASTS
9.1 CHALLENGES AND OPPORTUNITIES IN TBI R&D
9.2 FINANCIAL FORECASTS FOR THE TRAUMATIC BRAIN INJURY MARKET
10. FUTURE TRENDS IN TBI RESEARCH
10.1 MEDICAL IMAGING: THE HELPING HAND
10.2 INDUSTRY COLLABORATION: THE BIG AND THE SMALL
10.3 GENDER, AGE AND RELATED CONSIDERATIONS
10.4 PSYCHOLOGICAL AND SOCIAL ISSUES
10.5 REGULATORY ISSUES
10.6 COMPLEX PROBLEM: COMPLEX SOLUTION
10.7 NEW DIRECTIONS
APPENDIX I: KEY COMPANIES AND INSTITUTIONS INVOLVED IN TRAUMATIC BRAIN
INJURY RESEARCH
TABLES
TABLE 4.1 PATENT EXPIRATION DATES FOR SELECTED PRODUCTS
TABLE 5.1 THE GLASGOW COMA SCALE
TABLE 5.2 THE RANCHOS LOS AMIGOS SCALE
TABLE 5.3 TOOLS FOR DIAGNOSING THE SEVERITY OF TRAUMATIC BRAIN INJURY
TABLE 5.4 THE GLASGOW OUTCOME SCALE
TABLE 5.5 THE DISABILITY RATING SCALE
TABLE 5.6 THE DISABILITY RATING SCALE - INTERPRETATION OF SCORES
TABLE 5.7 INCIDENCE OF RECOVERY OF CONSCIOUSNESS AND FUNCTION IN ADULTS
AND CHILDREN IN A PERSISTENT VEGETATIVE STATE (PVS) AFTER TRAUMATIC OR
NONTRAUMATIC BRAIN INJURY
TABLE 5.8 COMMON CONSEQUENCES OF TRAUMATIC BRAIN INJURY
TABLE 7.1 SPORTS-RELATED HEAD INJURIES BY TYPE OF SPORT (2007)
TABLE 7.2 TBI MORTALITY RATE BY 100,000 POPULATION IN SELECT
COUNTRIES/REGIONS
TABLE 7.3 BURDEN OF NEUROLOGICAL DISORDERS, IN YEARS OF HEALTHY LIFE LOST
TO DISABILITY (YLDS), AS PERCENTAGE OF TOTAL, BY CAUSE - PROJECTIONS FOR 2005,
2015 AND 2030
TABLE 8.1 DIFFICULTIES FACING DESIGNERS OF TBI CLINICAL TRIALS
TABLE 8.2 OVERVIEW OF TRAUMATIC BRAIN INJURY PIPELINE
TABLE 9.1 KEY CHALLENGES AND OPPORTUNITIES IN TBI R&D
TABLE 9.2 ESTIMATES OF PEAK SALES AND POTENTIAL LAUNCH DATES FOR SELECT
TBI PIPELINE CANDIDATES
GRAPHS
GRAPH 5.1 TRAUMATIC BRAIN INJURY CASES BY CAUSE
GRAPH 5.2 TRAUMATIC BRAIN INJURY CASES BY SEVERITY
GRAPH 6.1 ESTIMATE OF DIRECT AND INDIRECT COSTS OF TRAUMATIC BRAIN INJURY
AS PERCENTAGE OF TOTAL GLOBAL COSTS PER ANNUM
GRAPH 7.1 NUMBER OF ROAD ACCIDENTS, 1994-2004
GRAPH 7.2 THE NUMBER OF PERSONS KILLED IN ROAD ACCIDENTS, 1994-2004
GRAPH 7.3 THE NUMBER OF PERSONS INJURED IN ROAD ACCIDENTS, 1994-2004
GRAPH 7.4 CASES OF TRAUMATIC BRAIN INJURY BY CAUSE IN THE UNITED STATES
GRAPH 7.5 ETIOLOGY OF TRAUMATIC BRAIN INJURIES IN THE UNITED STATES
GRAPH 7.6 TOP TEN CAUSES OF HEAD INJURIES IN CHILDREN AGED 14 AND YOUNGER
GRAPH 7.7 EXTERNAL CAUSES OF TRAUMATIC BRAIN INJURY IN SELECTED
GEOGRAPHICAL AREAS
GRAPH 9.1 FORECAST VALUE OF THE TRAUMATIC BRAIN INJURY MARKET IN THE
UNITED STATES 2015-2020
